Congress is renewing its previous efforts to make Medicare reimbursement of pharmacy testing permanent—here’s what that could mean for labs.
So far, it appears many post-PHE COVID-19 tests will be panels for detecting and differentiating among multiple respiratory viruses.
The end of the COVID-19 public health emergency on May 11 also brings certain flexibilities for labs and other providers to an end.
CMS recently issued long-awaited guidance on post-PHE changes to Medicare coverage of SARS-CoV-2 diagnostic tests.
COVID-19 test makers will either have to get full marketing approval, or take the product off the market.